ClinicalTrials.gg
CompletedNCT03066219Updated May 1, 2026Results posted

Safety and Efficacy of BRM421 for Dry Eye Syndrome

A Phase 2 interventional study of BRM421 and Placebo in Dry Eye Syndrome, sponsored by BRIM Biotechnology Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by BRIM Biotechnology Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
157
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
134th of 473
157 · median 60
Started
2017
with 15 others
Phase 2
97 of 544
5 open now
Registered
234th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 134th largest by enrollment of the 473 interventional ones that give a count, is one of 16 that started in 2017, is one of 97 in phase 2, and was the 234th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.

Read the detailed description

This is a multi-center, double-masked, randomized, vehicle-controlled, phase 2 study in approximately 150 subjects. (75 per treatment arm).

03

Conditions studied

  • Dry Eye Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be at least 18 years of age;
  • Provide written ;
  • Have a reported history of dry eye for at least 6 months prior to enrollment;
  • Have a history of use of eye drops

Exclusion criteria

Exclusion Criteria:

  • Have any slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
  • Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
  • Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;
  • Have used any eye drops within 2 hours of Visit 1;
  • Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
  • Be a woman of who is not using an acceptable means of ; acceptable methods of contraception
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
157 participants (actual)

Study arms

  • Active comparator
    BRM421 Ophthalmic Solution

    The active control with BRM421 solution

    Drug: BRM421

  • Placebo comparator
    Placebo

    The vehicle solution

    Drug: Placebo

Interventions

  • DrugBRM421

    0.03%(w/v) BRIM421 ophthalmic solution

  • DrugPlacebo

    vehicle ophthalmic drops

06

What researchers measure

Primary outcomes

  1. Sign: Corneal Fluorescein Staining Score

    The staining was graded with the Ora Calibra® Corneal and Conjunctival Staining Scale. The ocular surface was divided into three regions, including superior, central and inferior region. The following scale was used to grade staining of the each region. Half (0.5) grade increments may be used. The total score of corneal fluorescein staining was calculated as the sum of three regions, the score range is 0 (minimum) to 12 (maximum). None 0 = no staining Trace 1 = occasional Mild 2 = countable Moderate 3 = uncountable, but not confluent Severe 4 = confluent

    Time frame: change from baseline to week 4

  2. Symptom: Ocular Discomfort Score

    Ocular discomfort scores was subjectively graded by the subjects according to the following Ora Calibra® Ocular Discomfort Scale, rating each eye separately, the score range is 0 (minimum) to 4 (maximum). 0 = no discomfort 1. = intermittent awareness 2. = constant awareness 3. = intermittent discomfort 4. = constant discomfort

    Time frame: change from baseline to week 4

Secondary outcomes

  1. Tear Film Break-up Time

    The examiner was instilled 5 uL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival cul-de-sac of each eye. With the aid of a slit-lamp, the examiner monitored the integrity of the tear film, noting the time (seconds) it takes to form micelles from the time that the eye is opened.

    Time frame: change from baseline to week 4

  2. Conjunctival Redness

    Conjunctival redness was graded according to the following scale: Half (0.5) unit increments may be used. None 0 = Normal, without vasodilation Trace 1 = Trace ciliary or conjunctival vasodilation Mild 2 = Broad ciliary vasodilation; Moderate 3 = Broad ciliary and slight, horizontal conjunctival vasodilation Severe 4 = Broad ciliary and prominent, horizontal conjunctival vasodilation

    Time frame: change from baseline to week 4

  3. Ocular Surface Disease Index (OSDI)©

    OSDI scores was subjectively graded by the subjects according to the Ocular Surface and Disease Index (OSDI) Scale. Patients scored each question from 0 to 4 (higher score means more severe), and the OSDI score is the sum of total 12 questions. The score range is 0 (minimum) to 48 (maximum).

    Time frame: change from baseline to week 4

07

Results

Posted May 1, 2026

Participant flow

Participant flow — Overall Study
MilestoneBRM421 Ophthalmic SolutionPlacebo
Started7879
Completed7675
Not completed24

Outcome measures

PrimarySign: Corneal Fluorescein Staining Score

The staining was graded with the Ora Calibra® Corneal and Conjunctival Staining Scale. The ocular surface was divided into three regions, including superior, central and inferior region. The following scale was used to grade staining of the each region. Half (0.5) grade increments may be used. The total score of corneal fluorescein staining was calculated as the sum of three regions, the score range is 0 (minimum) to 12 (maximum). None 0 = no staining Trace 1 = occasional Mild 2 = countable Moderate 3 = uncountable, but not confluent Severe 4 = confluent

Time frame:
change from baseline to week 4
Reported as:
Mean · score on a scale
Sign: Corneal Fluorescein Staining Score
score on a scaleBRM421 Ophthalmic SolutionPlacebo
Sign: Corneal Fluorescein Staining Score-1.06 (-1.5 to -0.62)-1.16 (-1.61 to -0.71)
PrimarySymptom: Ocular Discomfort Score

Ocular discomfort scores was subjectively graded by the subjects according to the following Ora Calibra® Ocular Discomfort Scale, rating each eye separately, the score range is 0 (minimum) to 4 (maximum). 0 = no discomfort 1. = intermittent awareness 2. = constant awareness 3. = intermittent discomfort 4. = constant discomfort

Time frame:
change from baseline to week 4
Reported as:
Mean · score on a scale
Symptom: Ocular Discomfort Score
score on a scaleBRM421 Ophthalmic SolutionPlacebo
Symptom: Ocular Discomfort Score0.41 (0.14 to 0.67)0.16 (-0.14 to 0.46)
SecondaryTear Film Break-up Time

The examiner was instilled 5 uL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival cul-de-sac of each eye. With the aid of a slit-lamp, the examiner monitored the integrity of the tear film, noting the time (seconds) it takes to form micelles from the time that the eye is opened.

Time frame:
change from baseline to week 4
Reported as:
Mean · seconds
Tear Film Break-up Time
secondsBRM421 Ophthalmic SolutionPlacebo
Tear Film Break-up Time-0.165 (-0.358 to 0.027)0.183 (-0.034 to 0.401)
SecondaryConjunctival Redness

Conjunctival redness was graded according to the following scale: Half (0.5) unit increments may be used. None 0 = Normal, without vasodilation Trace 1 = Trace ciliary or conjunctival vasodilation Mild 2 = Broad ciliary vasodilation; Moderate 3 = Broad ciliary and slight, horizontal conjunctival vasodilation Severe 4 = Broad ciliary and prominent, horizontal conjunctival vasodilation

Time frame:
change from baseline to week 4
Reported as:
Mean · score on a scale
Conjunctival Redness
score on a scaleBRM421 Ophthalmic SolutionPlacebo
Conjunctival Redness-0.14 (-0.3 to 0.03)-0.1 (-0.27 to 0.07)
SecondaryOcular Surface Disease Index (OSDI)©

OSDI scores was subjectively graded by the subjects according to the Ocular Surface and Disease Index (OSDI) Scale. Patients scored each question from 0 to 4 (higher score means more severe), and the OSDI score is the sum of total 12 questions. The score range is 0 (minimum) to 48 (maximum).

Time frame:
change from baseline to week 4
Reported as:
Mean · score on a scale
Ocular Surface Disease Index (OSDI)©
score on a scaleBRM421 Ophthalmic SolutionPlacebo
Ocular Surface Disease Index (OSDI)©-3.89 (-6.33 to -1.45)-3.04 (-5.14 to -0.94)

Adverse events

Collected over 6 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BRM421 Ophthalmic Solution0/78 (0%)0/78 (0%)4/78 (5.1%)
Placebo0/79 (0%)0/79 (0%)3/79 (3.8%)
Most frequent other events
Most frequent other events
EventBRM421 Ophthalmic SolutionPlacebo
instillation site painEye disorders4/783/79

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)BRM421 Ophthalmic SolutionPlaceboTotal
<=18 years000
Between 18 and 65 years414182
>=65 years373875
Age, Continuous
Age, Continuous(years)BRM421 Ophthalmic SolutionPlaceboTotal
Mean62.7 ± 12.5763.0 ± 11.7862.9 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)BRM421 Ophthalmic SolutionPlaceboTotal
Female5359112
Male252045
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BRM421 Ophthalmic SolutionPlaceboTotal
Hispanic or Latino448
Not Hispanic or Latino7475149
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BRM421 Ophthalmic SolutionPlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American112
White7578153
More than one race101
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)BRM421 Ophthalmic SolutionPlaceboTotal
United States7879157
Ocular Discomfort
Ocular Discomfort(Participants)BRM421 Ophthalmic SolutionPlaceboTotal
Count of participants7879157
Burning
Burning(Participants)BRM421 Ophthalmic SolutionPlaceboTotal
Count of participants7879157

3 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Central Maine Eye Care
    Lewiston, Maine 04240, United States
  • Andover Eye Associates
    Andover, Massachusetts 01810, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in May 2017, 3 months.

Results were first posted in May 2026, 8 years 11 months after primary completion.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 3 months is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2017
First posted
Feb 28, 2017
StartActual
Feb 7, 2017
Primary completionActual
May 20, 2017
CompletionActual
Jun 28, 2017
Results first posted
May 1, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03066219
Lead sponsor
BRIM Biotechnology Inc.
Responsible party
Sponsor
First posted
Feb 28, 2017
Start date
Feb 7, 2017
Primary completion
May 20, 2017
Completion
Jun 28, 2017
Results posted
May 1, 2026
Last update
May 1, 2026

Study contacts

Gail Torkildsen, MD
principal investigator · Andover Eye Associates
John Lonsdale, MD
principal investigator · Central Maine Eye Care

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulipiftide

Start the discussion